Soleno Therapeutics Stock Dives After Its Meteoric Rise on Positive Study Results

Soleno Therapeutics stock fell sharply Wednesday, reversing a small portion of its meteoric gains from the previous session.

But smaller biopharmaceutical stocks are notoriously volatile. Soleno stock dropped 15% to $22.90 in recent trading Wednesday, although the shares are still up about 1,056% so far this year, largely thanks to Tuesday’s surge. The company has a market value of $268 million. Prader-Willi Syndrome affects metabolism, and its hallmark symptom is hyperphagia—a chronic feeling of intense, persistent hunger and an intense drive to consume food. Soleno said Tuesday that DCCR showed promise in addressing hyperphagia in a recent clinical development program, and spurring its stock to take off.

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trialPliant Therapeutics Inc. shares gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatment for a chronic...
Source: MarketWatch - 🏆 3. / 97 Read more »

Amgen discloses more than $400 million stake in recent IPO Neumora TherapeuticsAn Amgen disclosure of a large stake in Neumora Therapeutics indicated the value of its investment in the biotech, which recently went public, has tripled.
Source: MarketWatch - 🏆 3. / 97 Read more »